植入型心律转复除颤器一级预防的卫生经济学研究进展  

Advance in Economic Analysis for ICD Primary Prevention

作　　者：曾治宇[1,2] 林娜 张明东[1] 张澍 ZENG Zhiyu;LIKf Na;ZHANG Mingdong;ZHANG Shu(Medical Division of Boston Scientific International Medical Trading（Shanghai）Company Limited,Beijing 100125,China;School of Public Health,Peking University,Beijing 100191,China;center of Arrhythmia,Chinese Academy of Medical Sciences,Fuwai Hospital,Beijing 100037,China;Chinese Journal of Cardiac Arrhythmias,Beijing 100037,China)

机构地区：[1]波科国际医疗贸易(上海)有限公司医学部,北京100125 [2]北京大学公共卫生学院,北京100191 [3]中国医学科学院阜外医院心律失常诊治中心,北京100037 [4]中华心律失常学杂志编辑部,北京100037

出　　处：《心血管病学进展》2018年第3期320-323,共4页Advances in Cardiovascular Diseases

摘　　要：简要介绍植入型心律转复除颤器一级预防的临床试验及相关的卫生经济学分析。植入型心律转复除颤器一级预防的卫生经济学分析影响因素众多,结果差异也较大,增量成本-效果比从$8 539至44 736。应加强心脏性猝死高危患者的识别,关注器械的技术进步。在中国宜开展相应的卫生经济学研究,为合理分配有限的医疗资源提供数据。This review briefly introduces the clinical trials of primary prevention about implantable cardioverter defibrillator（ICD） and relevant economic analyses. Due to varied influencing factors of ICD primary prevention economic analysis, the incremental cost-effectiveness ratio（ICER） ranged from $8,539 to €44,736. It is important to focus on identifying the high risk patients and pay attention to device technological improvement. Related economic analysis of ICD primary prevention should be conducted in China to provide data for beter distribution of limited health care resources.

关 键 词：植入型心律转复除颤器 一级预防 卫生经济学 

分 类 号：R318.11[医药卫生—生物医学工程] R45[医药卫生—基础医学]